Impact of malaria on shaping immunity to EBV in the etiology of Burkitt lymphoma

疟疾对伯基特淋巴瘤病因中 EBV 免疫力的影响

• 批准号: 10381202
• 负责人: ANN M MOORMANN
• 金额: $ 15.82万
• 依托单位: UNIV OF MASSACHUSETTS MED SCH WORCESTER
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-10 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10381202
• 关键词: 2019-nCoV; Address; Administrative Supplement; Africa; African Burkitt' s lymphoma; Age; Antibodies; Antibody Response; Antigens; Area; Biological Assay; Breathing; Burkitt Lymphoma; COVID-19; COVID-19 pandemic; COVID-19 testing; COVID-19 vaccine; Cancer Control; Cancer Patient; Caring; Cellular Phone; Child; Childhood; Collection; Communities; Coronavirus; Country; Custom; Data; Data Collection; Databases; Decision Making; Devices; Diagnosis; Enrollment; Etiology; Event; Focus Groups; Funding; Government; Health; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Technology; Health system; Heart Rate; Home; Hospitals; Human Herpesvirus 4; Immune; Immunity; Immunocompromised Host; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Incidence; Infection; Infrastructure; Institution; Instruction; Interview; Kenya; Laboratories; Language; Lateral; Learning; Long-Term Care; Malaria; Malignant Childhood Neoplasm; Malignant Neoplasms; Measures; Medical; Membrane Proteins; Methods; Molecular; Monitor; Nucleoproteins; Organ; Outcome; Outpatients; Oxygen; Parents; Participant; Patients; Physical activity; Physiological; Process; Protocols documentation; Public Health; Quasi-experiment; Questionnaires; RADx; RNA; Recovery; Reporting; Research Personnel; Resources; SARS-CoV-2 infection; SARS-CoV-2 variant; Sampling; Schedule; Serology; Seroprevalences; Shapes; Skin Temperature; Surveys; System; T-Lymphocyte; Technology; Testing; Time; Training; Travel; Trust; United States National Institutes of Health; Vaccination; Variant; Viral; Virus; Wrist; barrier to care; base; cancer care; cancer diagnosis; cancer prevention; cancer therapy; care seeking; cofactor; cohort; community engagement; compliance behavior; coronavirus disease; cost; cross reactivity; cytotoxicity; data sharing; digital; digital health; digital medicine; feasibility testing; fitbit; health care availability; health seeking behavior; healthcare community; heart rate variability; home test; immunoregulation; improved; improved outcome; infected B cell; informant; innovation; interest; mobile computing; nasal swab; news; pandemic disease; parent grant; parental influence; patient oriented; programs; psychosocial; remote sensing; research study; respiratory; response; rural area; saliva sample; salivary assay; serosurvey; smartphone Application; study population; survivorship; treatment research; tumor; user-friendly; vaccine efficacy; vaccine-induced immunity; wearable device; wearable sensor technology

This administrative supplement is in response to NOT-CA-21-033 and aims to investigate the impact of the COVID-19 pandemic on Kenyan children diagnosed with endemic Burkitt lymphoma (eBL). The parent R01 CA189806-06 investigates malaria-induced immunoregulatory mechanisms that influence T cell cytotoxicity against EBV-infected B cells and eBL tumors. Kenyan children diagnosed with eBL and a cohort of healthy are being followed longitudinally to test the parent study objectives. The timely addition of COVID-related studies will determine the impact of COVID-19 public health protocols put into place by the Kenyan government in April 2020, on access to care and overall survival for Kenyan children with eBL. The supplemental activities include: 1) implementing a Knowledge, Attitude and Practices (KAP) psychosocial survey to ask parents of children enrolled in our study about COVID-19 and COVID-19 vaccines in order to assess barriers to prompt diagnosis, out-patient treatment compliance and research study participation; 2) SARS-CoV-2 monthly serosurveys which are easily added to our existing multiplex Luminex seroprofiling assay that has been validated by Dr. Moormann’s NCI SeroNet partnership (NIH/NCI 1U01 CA261276-01) with the Frederick National Laboratory standards; 3) SARS-CoV-2 molecular testing to compare variants that infect cancer patients compared to healthy age-matched controls and which may have implications for vaccine efficacy; 4) testing the use of innovative and low-cost digital health technologies to monitor health metrics (skin temperature, breathing and heart rate, etc) of eBL patients during the course of their care when they are out- patients; 5) community engagement activities such as key-informant interviews and focus group discussions to learn more about the impact of the COVID-19 pandemic on cancer prevention and control programs that are well established in Kenya. The immediate outcomes from this supplemental study will be achieved within the year. We will determine how the COVID-19 public health measures have inadvertently impacted health-care access specific to cancer diagnosis and eBL survivorship. With community advice, we will implement strategies to overcome these obstacles, including exploring sustainable use of remote sensing, digital medicine technologies to monitor cancer recovery. If children in our study have been infected with SARS-CoV-2, then we will include this as a cofactor when testing the mechanistic objectives pertaining to immune regulation proposed in the parent study. We do not believe that SARS-CoV-2 will increase the incidence of eBL; however, we are still learning what this virus is capable of and its prolonged effects on multiple organs. In addition, our study will assess COVID-19 variants and vaccine efficacy for eBL patients compared to healthy children. COVID-19 vaccines were introduced in Kenya during March 2021 and we anticipate childhood vaccinations will be recommended to stop the pandemic. This is of concern for immunocompromised cancer patients, who may require a booster to achieve immune protection against SARS-CoV-2.

本行政补充是对 NOT-CA-21-033 的回应，旨在调查该法案的影响 被诊断患有地方性伯基特淋巴瘤 (eBL) 的肯尼亚儿童遭受了新冠病毒 (COVID-19) 的大流行。母R01 CA189806-06 研究疟疾诱导的影响 T 细胞毒性的免疫调节机制 对抗 EBV 感染的 B 细胞和 eBL 肿瘤。被诊断患有 eBL 的肯尼亚儿童和一群健康人 纵向跟踪以测试家长的研究目标。及时添加新冠病毒相关研究 将确定肯尼亚政府 4 月份实施的 COVID-19 公共卫生协议的影响 2020 年，关于肯尼亚 eBL 儿童获得护理和总体生存的问题。补充活动 包括： 1) 实施知识、态度和实践 (KAP) 心理社会调查，询问家长 儿童参加了我们有关 COVID-19 和 COVID-19 疫苗的研究，以评估提示障碍 诊断、门诊治疗依从性和研究参与； 2) SARS-CoV-2 每月一次 血清调查可轻松添加到我们现有的多重 Luminex 血清分析测定中，该测定已被 经 Moormann 博士与 Frederick 的 NCI SeroNet 合作伙伴关系 (NIH/NCI 1U01 CA261276-01) 验证 国家实验室标准； 3) SARS-CoV-2 分子检测以比较感染癌症的变异体 患者与健康年龄匹配的对照相比，这可能对疫苗功效产生影响； 4） 测试使用创新且低成本的数字健康技术来监测健康指标（皮肤 eBL患者在护理过程中外出时的体温、呼吸和心率等） 患者; 5) 社区参与活动，例如关键知情人访谈和焦点小组讨论，以 详细了解 COVID-19 大流行对癌症预防和控制计划的影响 在肯尼亚颇有建树。这项补充研究的直接结果将在 年。我们将确定 COVID-19 公共卫生措施如何无意中影响了医疗保健 访问特定于癌症诊断和 eBL 生存的信息。根据社区建议，我们将实施策略 克服这些障碍，包括探索遥感、数字医学的可持续利用 监测癌症康复的技术。如果我们研究中的儿童感染了 SARS-CoV-2，那么我们 在测试与免疫调节有关的机械目标时，将将此作为辅助因子 在家长研究中提出。我们不认为 SARS-CoV-2 会增加 eBL 的发病率；然而， 我们仍在了解这种病毒的能力及其对多个器官的长期影响。此外，我们的 研究将评估 eBL 患者与健康儿童相比的 COVID-19 变异体和疫苗功效。 肯尼亚于 2021 年 3 月推出了 COVID-19 疫苗，我们预计儿童疫苗接种将 建议遏制疫情。这是免疫功能低下的癌症患者所关心的，他们可能 需要加强剂来实现针对 SARS-CoV-2 的免疫保护。